Showing results (381-390 of 909) with videos related to
Sort By:
Pageof 91
Circulation|December 20, 2011
Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary diseaseMarc S Sabatine, David A Morrow, James A de Lemos, et al.The American Journal of Cardiology|April 11, 2020
Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)Marat Fudim, Jacob P Kelly, Todd J Brophy, et al.The Journal of Thoracic and Cardiovascular Surgery|February 9, 2021
Impact of donor blood type on outcomes after prolonged allograft ischemic timesPaul C Tang, Jonathan W Haft, Ienglam Lei, et al.European Heart Journal|January 5, 2011
Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological dataGerasimos S Filippatos, Mustafa I Ahmed, James D Gladden, et al.Circulation. Heart Failure|February 5, 2017
Serum Chloride and Sodium Interplay in Patients With Acute Myocardial Infarction and Heart Failure With Reduced Ejection Fraction: An Analysis From the High-Risk Myocardial Infarction Database InitiativeJoão Pedro Ferreira, Nicolas Girerd, Kevin Duarte, et al.European Journal of Heart Failure|February 21, 2020
Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trialsXavier Rossello, João Pedro Ferreira, Stuart J Pocock, et al.Journal of the American College of Cardiology|August 29, 2023
Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection FractionShingo Matsumoto, Toru Kondo, Pardeep S Jhund, et al.JACC. Heart Failure|January 14, 2020
Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection FractionMatteo Serenelli, Alice Jackson, Pooja Dewan, et al.Journal of the American College of Cardiology|July 2, 2013
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)Romain Eschalier, John J V McMurray, Karl Swedberg, et al.Diabetes, Obesity & Metabolism|September 28, 2021
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trialPeter Rossing, Rajiv Agarwal, Stefan D Anker, et al.Pageof 91